Skip to main content
Erschienen in: Medical Oncology 1/2014

01.01.2014 | Short Communication

Intact expression status of RASSF1A in acute myeloid leukemia

verfasst von: Davood Zare-Abdollahi, Shamsi Safari, Abolfazl Movafagh, Mojtaba Ghadiani, Sahand Riazi-Isfahani, Mir Davood Omrani

Erschienen in: Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

As a typical tumor suppressor gene, transcriptional silencing of ras-association domain family 1, isoform A (RASSF1A) is caused by biallelic methylation or the condition that one allele is methylated and then the other allele lost by allelic loss, as second hit. RASSF1A is inactivated epigenetically and thus down-regulated in many solid tumors. In summary, for the first time, we analyzed the expression status of RASSF1A in a cohort of 56 de novo acute myeloid leukemia (AML) patients using quantitative real-time polymerase chain reaction. Results of our study indicate that patients with AML exhibited no differences in the RASSF1A gene expression comparing to normal controls. In conclusion, expression status of RASSF1A remained intact in our target samples, indicating that RASSF1A expression variation does not participate in the pathogenesis and the progression of AML.
Literatur
1.
Zurück zum Zitat Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.PubMedCrossRef Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.PubMedCrossRef
2.
Zurück zum Zitat Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.PubMedCrossRef Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.PubMedCrossRef
3.
Zurück zum Zitat Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114–28.PubMed Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114–28.PubMed
4.
Zurück zum Zitat Ahn EY, et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 2013;11(7):748–58.PubMedCrossRef Ahn EY, et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 2013;11(7):748–58.PubMedCrossRef
5.
Zurück zum Zitat Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286(8):6253–61.PubMedCrossRef Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286(8):6253–61.PubMedCrossRef
6.
Zurück zum Zitat Tan KO, et al. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802–7.PubMedCrossRef Tan KO, et al. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802–7.PubMedCrossRef
7.
Zurück zum Zitat Vos MD, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281(8):4557–63.PubMedCrossRef Vos MD, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281(8):4557–63.PubMedCrossRef
8.
Zurück zum Zitat Deng ZH, et al. Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol. 2008;14(9):1437–43.PubMedCrossRef Deng ZH, et al. Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol. 2008;14(9):1437–43.PubMedCrossRef
9.
Zurück zum Zitat Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9.PubMedCrossRef Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9.PubMedCrossRef
10.
Zurück zum Zitat Agathanggelou A, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20(12):1509–18.PubMedCrossRef Agathanggelou A, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20(12):1509–18.PubMedCrossRef
11.
Zurück zum Zitat Harada K, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345–9.PubMedCrossRef Harada K, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345–9.PubMedCrossRef
12.
Zurück zum Zitat Wong IH, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004;10(3):994–1002.PubMedCrossRef Wong IH, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004;10(3):994–1002.PubMedCrossRef
13.
Zurück zum Zitat Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.PubMedCrossRef Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.PubMedCrossRef
14.
Zurück zum Zitat Barletta E, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749–55.PubMedCrossRef Barletta E, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749–55.PubMedCrossRef
15.
Zurück zum Zitat Bennett JM, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103(4):620–5.PubMedCrossRef Bennett JM, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103(4):620–5.PubMedCrossRef
16.
Zurück zum Zitat Dastugue N, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9(9):1491–8.PubMed Dastugue N, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9(9):1491–8.PubMed
17.
Zurück zum Zitat Greenwood MJ, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245–52.PubMedCrossRef Greenwood MJ, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245–52.PubMedCrossRef
18.
Zurück zum Zitat Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17(12):2474–86.PubMedCrossRef Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17(12):2474–86.PubMedCrossRef
19.
Zurück zum Zitat Johan MF, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60–5.PubMedCrossRef Johan MF, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60–5.PubMedCrossRef
20.
Zurück zum Zitat Avramouli A, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130–2.PubMedCrossRef Avramouli A, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130–2.PubMedCrossRef
21.
Zurück zum Zitat Zhang H, et al. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 2013;27(1):232–42.PubMedCrossRef Zhang H, et al. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 2013;27(1):232–42.PubMedCrossRef
22.
Zurück zum Zitat Florean C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581–609.PubMedCrossRef Florean C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581–609.PubMedCrossRef
23.
Zurück zum Zitat Nakao M, et al. Epigenetic system: a pathway to malignancies and a therapeutic target. Int J Hematol. 2004;80(2):103–7.PubMedCrossRef Nakao M, et al. Epigenetic system: a pathway to malignancies and a therapeutic target. Int J Hematol. 2004;80(2):103–7.PubMedCrossRef
Metadaten
Titel
Intact expression status of RASSF1A in acute myeloid leukemia
verfasst von
Davood Zare-Abdollahi
Shamsi Safari
Abolfazl Movafagh
Mojtaba Ghadiani
Sahand Riazi-Isfahani
Mir Davood Omrani
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0770-x

Weitere Artikel der Ausgabe 1/2014

Medical Oncology 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.